TWST
Neutral signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Financial indicators Unavailable or mixed. Current ratio 3.64 · operating margin -36% — readings disagree
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Supports a bullish reading. Interesting trend — weekly bias up
VENTE TOTALE: 436 139 titres (~65 429 077,11 $ US)
- Insiders
- Leproust Emily M.BLAKE KATRYN
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$65,429,077
Avg sell (VWAP, 90d window) $122.51 vs last close $182.83 (+49.2%)
- Last activity
- 2026-09-24
- Liquidity
- Liquid $359,425,259/day · 20d vol
- Last synced
-
2026-09-25 21:11:00
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-21 | Cho Dennis | Sell | 348 | $165.49 | $57,591 | Form 4 |
| 2026-09-21 | Green Paula | Sell | 294 | $165.49 | $48,654 | Form 4 |
| 2026-09-21 | Leproust Emily M. | Sell | 1,687 | $165.49 | $279,183 | Form 4 |
| 2026-09-17 | Leproust Emily M. | Sell | 869 | $163.39 | $141,988 | Form 4 |
| 2026-09-08 | Cho Dennis | Sell | 412 | $122.62 | $50,521 | Form 4 |
| 2026-09-08 | Green Paula | Sell | 907 | $122.62 | $111,220 | Form 4 |
| 2026-09-08 | Leproust Emily M. | Sell | 2,302 | $122.62 | $282,280 | Form 4 |
| 2026-09-08 | WERNER ROBERT F. | Sell | 238 | $122.62 | $29,185 | Form 4 |
| 2026-08-25 | Leproust Emily M. | Sell | 1,093 | $154.45 | $168,809 | Form 4 |
| 2026-08-24 | WERNER ROBERT F. | Sell | 854 | $140.77 | $120,220 | Form 4 |
| 2026-08-21 | Cho Dennis | Sell | 1,598 | $139.07 | $222,227 | Form 4 |
| 2026-08-21 | Finn Patrick John | Sell | 4,046 | $139.07 | $562,661 | Form 4 |
| 2026-08-21 | Green Paula | Sell | 1,360 | $139.07 | $189,130 | Form 4 |
| 2026-08-21 | Laponis Adam | Sell | 1,965 | $139.07 | $273,265 | Form 4 |
| 2026-08-21 | Leproust Emily M. | Sell | 6,639 | $139.07 | $923,259 | Form 4 |
| 2026-08-21 | WERNER ROBERT F. | Sell | 669 | $139.07 | $93,035 | Form 4 |
| 2026-08-19 | Cho Dennis | Sell | 14,205 | $129.75 | $1,843,099 | Form 4 |
| 2026-08-18 | Finn Patrick John | Sell | 2,000 | $122.58 | $245,162 | Form 4 |
| 2026-08-12 | BLAKE KATRYN | Sell | 2,240 | $122.88 | $275,251 | Form 4 |
| 2026-08-12 | Leproust Emily M. | Sell | 19,952 | $125.08 | $2,495,508 | Form 4 |
| 2026-08-10 | Leproust Emily M. | Sell | 113,318 | $125.16 | $14,183,051 | Form 4 |
| 2026-08-07 | CHESS ROBERT | Sell | 18,417 | $110.89 | $2,042,261 | Form 4 |
| 2026-08-05 | Cho Dennis | Sell | 14,205 | $109.75 | $1,558,999 | Form 4 |
| 2026-08-03 | Cho Dennis | Sell | 1,070 | $85.32 | $91,294 | Form 4 |
| 2026-08-03 | Finn Patrick John | Sell | 2,888 | $85.32 | $246,408 | Form 4 |
| 2026-08-03 | Green Paula | Sell | 1,133 | $85.32 | $96,669 | Form 4 |
| 2026-08-03 | Leproust Emily M. | Sell | 5,101 | $85.32 | $435,223 | Form 4 |
| 2026-08-03 | WERNER ROBERT F. | Sell | 167 | $85.32 | $14,249 | Form 4 |
| 2026-07-23 | Finn Patrick John | Sell | 2,238 | $93.89 | $210,133 | Form 4 |
| 2026-07-09 | Laponis Adam | Sell | 2,399 | $94.33 | $226,307 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Neutral signalScored 2026-09-25
TWST shows genuine operational improvement with expanding gross margins and a narrowing loss trajectory, providing a solid fundamental foundation (liquidity score: 75, fundamentals trend: 65).
The first sentence of the analysis written for TWST on 2026-09-25 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 50.7% | 42.6% | 36.6% | 41.4% | 39.1% | |
| Ebit Margin | -20.4% | -66.5% | -83.0% | -112.1% | -116.1% | |
| Ebitda Margin | -13.8% | -56.5% | -71.1% | -104.0% | -108.7% | |
| Operating Profit Margin | -36.2% | -70.6% | -88.6% | -115.3% | -115.4% | |
| Pretax Profit Margin | -20.4% | -66.5% | -83.0% | -112.1% | -116.4% | |
| Continuous Operations Profit Margin | -20.6% | -66.7% | -83.5% | -107.0% | -114.9% | |
| Net Profit Margin | -20.6% | -66.7% | -83.5% | -107.0% | -114.9% | |
| Bottom Line Profit Margin | -20.6% | -66.7% | -83.5% | -107.0% | -114.9% | |
| Current Ratio | 3.643 | 4.884 | 5.786 | 6.579 | 8.667 | |
| Quick Ratio | 3.333 | 4.545 | 5.349 | 6.146 | 8.163 | |
| Solvency Ratio | -0.313 | -1.252 | -1.146 | -1.171 | -1.174 | |
| Cash Ratio | 2.003 | 3.187 | 3.907 | 4.177 | 7.388 | |
| Price To Earnings Ratio | -21.646 | -12.550 | -5.628 | -8.723 | -33.959 | |
| Price To Earnings Growth Ratio | 0.339 | 0.000 | 0.517 | -0.309 | 2.886 | |
| Forward Price To Earnings Growth Ratio | 0.339 | 0.000 | 0.517 | -0.309 | 2.886 | |
| Price To Earnings Diluted Ratio | -21.646 | -12.550 | -5.628 | -8.723 | -33.959 | |
| Price To Earnings Diluted Growth Ratio | 0.339 | 0.000 | 0.517 | -0.309 | 2.886 | |
| Price To Book Ratio | 3.558 | 5.545 | 1.849 | 2.406 | 8.886 | |
| Price To Sales Ratio | 4.469 | 8.375 | 4.702 | 9.328 | 39.003 | |
| Price To Free Cash Flow Ratio | -22.252 | -37.895 | -6.769 | -8.393 | -37.051 | |
| Price To Operating Cash Flow Ratio | -35.336 | -40.896 | -8.089 | -15.266 | -45.984 | |
| Debt To Assets Ratio | 0.214 | 0.138 | 0.121 | 0.099 | 0.090 | |
| Debt To Equity Ratio | 0.290 | 0.180 | 0.151 | 0.120 | 0.108 | |
| Debt To Capital Ratio | 0.225 | 0.152 | 0.131 | 0.107 | 0.098 | |
| Long Term Debt To Capital Ratio | 0.115 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.357 | 1.300 | 1.245 | 1.218 | 1.209 | |
| Working Capital Turnover Ratio | 1.456 | 0.999 | 0.572 | 0.412 | 0.338 | |
| Operating Cash Flow Ratio | -0.521 | -0.903 | -1.943 | -1.372 | -1.780 | |
| Operating Cash Flow Sales Ratio | -0.126 | -0.205 | -0.581 | -0.611 | -0.848 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.588 | 1.079 | 1.195 | 1.819 | 1.241 | |
| Debt Service Coverage Ratio | -3.821 | -6,112.586 | -35,060.600 | -2,515.863 | -73.987 | |
| Interest Coverage Ratio | 0.000 | -7,614.862 | -43,431.800 | -2,934.700 | -416.147 | |
| Short Term Operating Cash Flow Coverage Ratio | -3.446 | 0.000 | 0.000 | 0.000 | -72.322 | |
| Operating Cash Flow Coverage Ratio | -0.347 | -0.754 | -1.515 | -1.311 | -1.784 | |
| Capital Expenditure Coverage Ratio | -1.701 | -12.627 | -5.129 | -1.221 | -4.148 | |
| Dividend Paid And Capex Coverage Ratio | -1.701 | -12.627 | -5.129 | -1.221 | -4.148 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -31.427 | -14.034 | -5.513 | -7.630 | -33.066 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 50.7% | ▲8.1% | ▲8.6% |
| Ebit Margin | -20.4% | ▲46.1% | ▲59.2% |
| Ebitda Margin | -13.8% | ▲42.6% | ▲57.0% |
| Operating Profit Margin | -36.2% | ▲34.4% | ▲49.0% |
| Pretax Profit Margin | -20.4% | ▲46.1% | ▲59.3% |
| Continuous Operations Profit Margin | -20.6% | ▲46.1% | ▲57.9% |
| Net Profit Margin | -20.6% | ▲46.1% | ▲57.9% |
| Bottom Line Profit Margin | -20.6% | ▲46.1% | ▲57.9% |
| Current Ratio | 3.643 | ▼-1.241 | ▼-2.269 |
| Quick Ratio | 3.333 | ▼-1.212 | ▼-2.174 |
| Solvency Ratio | -0.313 | ▲0.939 | ▲0.698 |
| Cash Ratio | 2.003 | ▼-1.185 | ▼-2.130 |
| Price To Earnings Ratio | -21.646 | ▼-9.096 | ▼-5.145 |
| Price To Earnings Growth Ratio | 0.339 | ▲0.339 | ▼-0.348 |
| Forward Price To Earnings Growth Ratio | 0.339 | ▲0.339 | ▼-0.348 |
| Price To Earnings Diluted Ratio | -21.646 | ▼-9.096 | ▼-5.145 |
| Price To Earnings Diluted Growth Ratio | 0.339 | ▲0.339 | ▼-0.348 |
| Price To Book Ratio | 3.558 | ▼-1.987 | ▼-0.890 |
| Price To Sales Ratio | 4.469 | ▼-3.906 | ▼-8.706 |
| Price To Free Cash Flow Ratio | -22.252 | ▲15.642 | ▲0.220 |
| Price To Operating Cash Flow Ratio | -35.336 | ▲5.559 | ▼-6.222 |
| Debt To Assets Ratio | 0.214 | ▲0.075 | ▲0.082 |
| Debt To Equity Ratio | 0.290 | ▲0.111 | ▲0.120 |
| Debt To Capital Ratio | 0.225 | ▲0.073 | ▲0.082 |
| Long Term Debt To Capital Ratio | 0.116 | ▲0.116 | ▲0.092 |
| Financial Leverage Ratio | 1.357 | ▲0.058 | ▲0.091 |
| Working Capital Turnover Ratio | 1.456 | ▲0.457 | ▲0.701 |
| Operating Cash Flow Ratio | -0.521 | ▲0.382 | ▲0.783 |
| Operating Cash Flow Sales Ratio | -0.127 | ▲0.078 | ▲0.348 |
| Free Cash Flow Operating Cash Flow Ratio | 1.588 | ▲0.509 | ▲0.203 |
| Debt Service Coverage Ratio | -3.821 | ▲6108.765 | ▲8749.550 |
| Interest Coverage Ratio | 0.000 | ▲7614.862 | ▲10879.502 |
| Short Term Operating Cash Flow Coverage Ratio | -3.446 | ▼-3.446 | ▲11.708 |
| Operating Cash Flow Coverage Ratio | -0.347 | ▲0.407 | ▲0.795 |
| Capital Expenditure Coverage Ratio | -1.701 | ▲10.926 | ▲3.264 |
| Dividend Paid And Capex Coverage Ratio | -1.701 | ▲10.926 | ▲3.264 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -31.427 | ▼-17.393 | ▼-13.093 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.68B | $2.62B | $1.15B | $1.90B | $5.16B | |
| Enterprise value | $1.64B | $2.48B | $960.1M | $1.62B | $4.76B | |
| EV / Sales | 4.35x | 7.92x | 3.92x | 7.93x | 35.96x | |
| EV / Op. cash flow | -34.38x | -38.69x | -6.74x | -12.98x | -42.39x | |
| EV / Free cash flow | -21.65x | -35.85x | -5.64x | -7.14x | -34.16x | |
| EV / EBITDA | -31.43x | -14.03x | -5.51x | -7.63x | -33.07x | |
| Net debt / EBITDA | 0.88x | 0.80x | 1.10x | 1.34x | 2.80x | |
| Current ratio | 3.64x | 4.88x | 5.79x | 6.58x | 8.67x | |
| Income quality | 0.61x | 0.31x | 0.70x | 0.57x | 0.74x | |
| Graham net-net | $2 | $3 | $4 | $7 | $8 | |
| Tax burden | 100.9% | 100.3% | 100.6% | 95.4% | 98.7% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.2% | |
| Working capital | $241.6M | $275.8M | $350.9M | $505.8M | $483.4M | |
| Invested capital | $488.8M | $537.4M | $694.6M | $865.8M | $629.8M | |
| Return on assets | -12.1% | -34.0% | -26.4% | -22.7% | -21.7% | |
| Operating ROA | -21.7% | -31.8% | -25.0% | -28.2% | -27.7% | |
| Return on tangible assets | -14.2% | -40.6% | -32.2% | -26.7% | -23.0% | |
| Return on equity | -16.4% | -44.2% | -32.8% | -27.6% | -26.2% | |
| Return on invested capital | -24.1% | -39.6% | -30.2% | -25.3% | -23.2% | |
| Return on capital employed | -24.8% | -40.6% | -30.9% | -27.0% | -23.9% | |
| Earnings yield | -4.6% | -8.0% | -17.8% | -11.5% | -2.9% | |
| Free cash flow yield | -4.5% | -2.6% | -14.8% | -11.9% | -2.7% | |
| Capex / Op. cash flow | -58.8% | -7.9% | -19.5% | -81.9% | -24.1% | |
| Capex / Depreciation | 112.7% | 16.1% | 94.8% | 616.8% | 277.5% | |
| Capex / Sales | 7.4% | 1.6% | 11.3% | 50.0% | 20.4% | |
| SG&A / Sales | 65.6% | 69.8% | 77.4% | 104.6% | 102.7% | |
| R&D / Sales | 21.3% | 29.0% | 43.6% | 59.1% | 52.2% | |
| Stock comp / Sales | 17.1% | 16.3% | 12.4% | 39.1% | 28.0% | |
| Intangibles / Total assets | 14.9% | 16.3% | 18.1% | 15.1% | 5.8% | |
| Days sales outstanding | 56d | 41d | 66d | 72d | 79d | |
| Days payables outstanding | 22d | 3d | 33d | 61d | 67d | |
| Operating cycle | 111d | 90d | 141d | 192d | 223d | |
| Cash conversion cycle | 89d | 86d | 108d | 131d | 155d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-35.8%EV / Sales ▼-45.1%EV / EBITDA ▼-123.9%EV / Op. cash flow ▲+4.315Earnings yield ▲+0.033
Profitability
Return on equity ▲+0.277Return on assets ▲+0.219Return on invested capital ▲+0.154Return on capital employed ▲+0.159Operating ROA ▲+0.101Income quality ▲+0.306Tax burden ▲+0.007
Efficiency
Days sales outstanding ▲+14.853Days payables outstanding ▲+18.509Operating cycle ▲+21.607Cash conversion cycle ▲+3.098Capex / Sales ▲+0.058R&D / Sales ▼-0.077
Balance-sheet strength
Current ratio ▼-1.241Net debt / EBITDA ▲+0.078Working capital ▼-34210000.000Invested capital ▼-48568000.000Intangibles / Total assets ▼-0.014
Change over 5 years
Valuation
Market cap ▼-67.4%EV / Sales ▼-87.9%EV / EBITDA ▲+5.0%EV / Op. cash flow ▲+8.018Earnings yield ▼-0.017
Profitability
Return on equity ▲+0.098Return on assets ▲+0.096Return on invested capital ▼-0.009Return on capital employed ▼-0.009Operating ROA ▲+0.060Income quality ▼-0.125Tax burden ▲+0.022
Efficiency
Days sales outstanding ▼-23.186Days payables outstanding ▼-45.638Operating cycle ▼-111.476Cash conversion cycle ▼-65.839Capex / Sales ▼-0.130R&D / Sales ▼-0.309
Balance-sheet strength
Current ratio ▼-5.025Net debt / EBITDA ▼-1.922Working capital ▼-241883000.000Invested capital ▼-141001000.000Intangibles / Total assets ▲+0.091
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2020-03-02 | Dwight Evans | Purchase | $1,001 - $15,000 |
Recent news
- 2026-09-25 Twist Bioscience Stock Hits New High, Then Retreats: What''s Happening? Twist Bioscience Corp. (NASDAQ:TWST) shares are trading lower Friday, pulling back after touching a fresh 52-week high near $192 earlier in the session. Here''s what you should know.
- 2026-09-22 3 Analysts, 3 Trades to Make Today Louis says buy the AI dip
- 2026-09-18 Why Twist Bioscience Stock Skyrocketed This Week The biotech will both contribute to and draw from its findings. It''ll also earn revenue from its participation.
- 2026-09-16 Beyond Hype: Twist Bioscience Secures Data Pipeline Role In Eli Lilly TuneLab Ecosystem Twist Bioscience Corporation (NASDAQ:TWST) on Wednesday announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Co. (NYSE:LLY).
- 2026-09-16 Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery [url="]Twist Bioscience Corporation[/url] (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced an agreement with Lilly TuneLab, a collabo
- 2026-09-16 Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). Twist is a provider of antibody characterization data services for TuneLab, including for AbLab, an antibody developability prediction model. TuneLab was created to accelerate biotech innovation by enabling participating compan.
- 2026-09-09 AI & Robotics in 2026: 16 Recent Developments for Investors If AI and robotics suddenly feel like they are moving faster, August gave investors plenty of evidence that the pace really is accelerating. We saw longer-running agents, faster and cheaper inference, AI systems reaching into laboratories and physical equipment, robots learning from fewer demonstrations, and new capital and infrastructure forming around commercial deployment.
- 2026-09-09 Twist Bioscience to Present at Baird 2026 Global Healthcare Conference SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in a fireside chat at the Baird 2026 Global Healthcare Conference on Tuesday, September 15, 2026 at 1:25 pm Eastern Time in New York City. The fireside chat will be webcast live and can be accessed by visiting the “In.
- 2026-08-25 Brandywine Managers LLC Invests $2.16 Million in Twist Bioscience Corporation $TWST Brandywine Managers LLC acquired a new position in shares of Twist Bioscience Corporation (NASDAQ: TWST) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 20,970 shares of the company''s stock, valued at approximately $2,157,000. Twist Bioscience comprises
- 2026-08-24 90,053 Shares in Twist Bioscience Corporation $TWST Acquired by Deutsche Bank AG Deutsche Bank AG acquired a new stake in Twist Bioscience Corporation (NASDAQ: TWST) in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 90,053 shares of the company''s stock, valued at approximately $9,265,000. Deutsche Bank AG owned about 0.14% of Twist